Patent and intellectual property risk
The company relies on proprietary enzyme and workflow technologies that must be protected from imitation or infringement claims.
- Scope
- Core product portfolio and licensing value
- Materiality
- high
Genovis
Genovis is a Swedish life science tools company that develops and markets enzyme-based products and related technologies for biopharmaceutical research, diagnostics, and drug development. Its portfolio includes SmartEnzymes, antibody labeling and glycan-remodeling technologies, and genomics reagents, with operations centered in Sweden and a U.S. subsidiary supporting North American sales.
| % | |
|---|---|
| SmartEnzymes and biochemical analysis | 45% Enzyme-based tools used for biochemical and biophysical analysis workflows. |
| Antibody conjugation | 30% Technologies and reagents for antibody labeling, remodeling, and ADC workflows. |
| Genomics | 15% Reagents and tools for genomics research, including RNA-related applications. |
| Services and custom solutions | 10% Application support, customized products, and customer-specific development work. |
Genovis sells to biopharmaceutical companies, biotech firms, and research organizations that need specialized tools for...
- Biopharmaceutical developersprimary
Buy enzyme tools and conjugation technologies for discovery, preclinical, and clinical development.
- Biotech and advanced therapy companiesprimary
Use ADC, gene therapy, and targeted delivery tools to build and test therapeutic candidates.
- Research institutions and academiasecondary
Purchase reagents and workflow tools for biochemical analysis and genomics research.
- Manufacturing and quality control teamssecondary
Use products to verify consistency and support production-stage analytical workflows.
Genovis is headquartered in Kävlinge, Sweden, where it develops and produces enzyme products and houses central support...
- •Headquarters and production are in Kävlinge, Sweden
- •European sales and global marketing are run from Sweden
- •North American sales are handled through Genovis Inc. in the U.S.
- •San Diego serves as a warehouse and logistics center
- •Local representation supports sales in several key markets
Genovis focuses on customer-driven innovation, new product launches, and deeper integration of its tools into customer...
01
Customer-driven product innovationshort-term
Close collaboration with users helps Genovis build tools that fit real workflows and improve adoption.
02
Broaden the portfolio through licensing and acquisitionsmedium-term
Access to proprietary technology expands the addressable market and supports differentiated offerings.
03
Embed products across the development chainmedium-term
Serving discovery, clinical, and manufacturing stages increases customer lifetime value and product relevance.
Genovis faces technology, patent, and launch-execution risk because its business depends on specialized products that...
Technology and product launch risk
New tools must work as expected and gain adoption in scientific workflows, or expected revenue may not materialize.
- Scope
- New product pipeline
- Materiality
- high
Foreign exchange risk
Expenses are mainly in SEK while revenue is largely in USD and EUR, creating translation and transaction exposure.
- Scope
- Operating profit and cash flow
- Materiality
- high
Customer demand cyclicality
Life science customers may delay purchases when research or development budgets tighten.
- Scope
- Order intake and launch timing
- Materiality
- medium
Production dependency risk
Reliance on external manufacturing capacity for some products can delay launches and constrain supply.
- Scope
- Selected product lines
- Materiality
- medium
Business combinations and intangible assets
SEQURNA acquisition and any future M&A
Goodwill impairment
Reported equity and operating results
Foreign currency translation
Operating profit and equity
Revenue recognition for product and custom orders
Quarterly comparability
Annovis Bio, Inc.
ANVS · Pharmaceutical Preparations
Genova Property Group
GPG.ST · Real Estate
Genova Property Group is a dynamic property company that combines stable cash flows from investment properties with investments in value-creating development projects.
Ericsson B
ERIC-B.ST · Telecommunications
AstraZeneca
AZN.ST · Health Care
Billerud
BILL.ST · Basic Materials
Beijer Ref
BEIJ-B.ST · Industrials
: 11/08/2026